Drug intelligence / Profile preview

TRB-031

Development stage: Preclinical
Lead developer: TRexBio

Overview

TRB-031 is a preclinical-stage biologic candidate designed to modulate regulatory T cell (Treg) pathways to restore immune homeostasis. Discovered using TRexBio's proprietary Deep Biology platform, the drug is intended for the treatment of immune-mediated diseases, including various autoimmune and inflammatory conditions. In early 2023, Eli Lilly and Company exercised its option to exclusively license TRB-031, along with two other Treg-targeting programs (TRB-041 and TRB-051), from TRexBio. At the time of the licensing agreement, TRB-031 was in the IND-enabling stage of development.

Beyond the preview

Go deeper on TRB-031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRB-031.

Explore the full profile